Prescribing overview
Elura and Entyce have different concentrations, species and indications; appetite response does not diagnose the underlying illness.
Key prescribing checks
- Elura should not be used in cats with acromegaly. Its glucose effects make diabetes history relevant; the label says use in diabetic cats may not be appropriate.
- Assess hydration, hepatic status and relevant cardiac concerns. Entyce labeling advises caution with hepatic dysfunction and renal insufficiency.
- Increased appetite does not identify or resolve the underlying illness. Record food intake, weight trend and adverse effects within the clinician’s monitoring plan.
Uses by species
Approval and evidence apply to the named product, species, route and indication. An extra-label use requires its own prescribing assessment; a human indication is not an animal approval.
Cats
US veterinary approval: EluraWeight-loss management with chronic kidney disease
Do not use with acromegaly.
Use / indication source ↗Dogs
US veterinary approval: EntyceAppetite stimulation
Use caution with hepatic/renal dysfunction, dehydration, cardiac disease or diabetes.
Use / indication source ↗Pharmacology & pharmacokinetics
Mechanism and clinical role
Ghrelin-receptor activation stimulates appetite and growth-hormone signaling; feline weight effects may involve food intake and metabolic changes.
Absorption, distribution, metabolism and elimination
Elura in fasted cats: rapid absorption, median peak 0.25 hours, half-life 1.12 hours; feeding reduces exposure.
Entyce in Beagles: mean peak 0.83 hours, half-life 1.19 hours and bioavailability 44%; these canine data do not establish feline disposition.
SAFETY REFERENCE · PRODUCT & SPECIES SPECIFIC
Contraindications & cautions
Contraindications identify circumstances where the source says a product should not be used. Precautions call for assessment or monitoring. Interactions identify combinations to review. They are distinct categories; this summary does not replace a full interaction check or the current product label.
Elura
US feline oral solution label.
Contraindications · when not to use
- Capromorelin hypersensitivity.
Precautions & monitoring
- Warning: do not use with acromegaly. Diabetes use is unevaluated and may be inappropriate; caution with cardiac disease, severe dehydration or hepatic dysfunction. Under-five-month and reproductive safety unstudied.
Entyce
US canine oral solution label.
Contraindications · when not to use
- Capromorelin hypersensitivity.
Precautions & monitoring
- Caution with hepatic/renal dysfunction, cardiac disease, severe dehydration or diabetes. Reproductive safety unevaluated; transient bradycardia/hypotension and hyperglycemia are reported.
Safety sources checked: . Selected label information; independent veterinary or veterinary-pharmacy review remains pending. A label for dogs, cats, horses or humans does not establish safety for another species.
Adverse effects
Vomiting, drooling, diarrhea and lethargy are reported. Transient bradycardia, hypotension and glucose increases require clinical consideration.
These are selected source-reported effects, not incidence estimates or an exhaustive list. Spontaneous postmarketing reports do not by themselves establish frequency or causality.
Dosing & administration
| Species & indication | Labeled regimen | Eligibility & source |
|---|---|---|
| CatsCKD-associated weight lossElura 20 mg/mL oral solution | 2 mg/kg (0.1 mL/kg) Oral · Once daily Response-guided; no fixed course in dosage section | For meal-fed cats offer food 30 minutes later. Label permits redosing if vomiting within 15 minutes or partial dose. Safety below 5 months unestablished. Verify full dosing label ↗ |
| DogsAppetite stimulationEntyce 30 mg/mL oral solution | 3 mg/kg Oral · Once daily Field-study effectiveness not evaluated beyond 4 days | Use supplied syringe; gently shake bottle. Do not transfer Elura volumes. Verify full dosing label ↗ |
Reproductive safety unestablished. Diabetic use requires particular caution.
Extra-label prescribing and food-animal residue requirements are separate from labeled regimens. FDA extra-label-use guidance ↗
Drug & supplement interactions
This is a selected interaction reference, not an automated or comprehensive combination checker. Reconcile prescription drugs, nonprescription products, supplements and recent treatment changes.
A product-specific interaction summary has not been established here. An empty list must not be interpreted as “no interactions.” Review the full source and a species-appropriate clinical reference.
Monitoring
Track food intake, weight, hydration, glucose risk and clinical disease trajectory.
Client counseling
Report weakness, thirst changes, digestive signs or unusual behavior; wash hands after dosing.
This section supports the veterinary team's discharge discussion; it does not replace the product’s Client Information Sheet where one is required.
Storage & handling
Secure bottles; rinse syringe/plunger and dry separately between doses.
Brands, formulations & ingredient identity
Active ingredients
capromorelin
Other searchable names: capromorelin tartrate
Elura and Entyce share the active moiety but are not automatically interchangeable products. Elura is 20 mg/mL and Entyce is 30 mg/mL; bottle volume instructions cannot be transferred between them.
The brands have different labeled species and indications. Document the exact brand and concentration in the prescription and administration record.
Capromorelin tartrate appears in chemical descriptions of the ingredient. It is a salt identity, not an additional appetite stimulant.
Shared ingredients do not establish interchangeable concentrations, routes, release properties, species labeling or regional availability.
Elura
- Formulation
- 20 mg/mL oral solution
- Label / product scope
- Cats
Labeled for weight loss with feline chronic kidney disease.
Product label / source ↗Entyce
- Formulation
- 30 mg/mL oral solution
- Label / product scope
- Dogs
Labeled for canine appetite stimulation; different concentration from Elura.
Product label / source ↗References & review status
Clinical reference updated October 16, 2026. Independent veterinary or veterinary-pharmacy review not yet completed. Evidence gaps remain explicitly identified; this page does not claim equivalence to a comprehensive, professionally reviewed veterinary formulary.
Search another medication or supplement →